Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype

British Journal of Clinical Pharmacology

Volumn 69, Issue 5, 2010, Pages 516-519

  Helsby, Nuala A ^a   Lo, Wing Yee ^a   Simpson, Ian J ^a,b   Voss, David M ^a,c   Logan, Kaye E ^d   Searle, Martin ^d   Schollum, John B W ^e   De Zoysa, Janak R ^b,f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c MIDDLEMORE HOSPITAL   (New Zealand)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e DUNEDIN HOSPITAL   (New Zealand)

^f NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

Acute interstitial nephritis; CYP2C19 genotype; Omeprazole

Indexed keywords

CYCLOGUANIL; CYTOCHROME P450 2C19; OMEPRAZOLE; PROGUANIL;

ADULT; AGED; ALLELE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INTERSTITIAL NEPHRITIS; MALE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL; OMEPRAZOLE; PHENOTYPE; PROTON PUMP INHIBITORS;

EID: 77950634823     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03623.x     Document Type: Article

References (10)

1. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, Voss D. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology 2006 11 : 381 385.
2. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008 64 : 935 951.
3. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 2005 44 : 1179 1189.
4. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991 31 : 689 692.
5. Goldstein JA, Blaisdell J. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 1996 272 : 210 218.
6. Woolf EJ, Matuszewski BK. Simultaneous determination of omeprazole and 5′-hydroxyomeprazole in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr A 1998 828 : 229 238.
7. Xie HG, Stein CM, Kim RB, Wilkinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999 9 : 539 549.
8. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 2008 65 : 767 774.
9. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996 23 : 1491 1497.
10. Sabolić I, Brown D, Verbavatz JM, Kleinman J. H(+)-ATPases of renal cortical and medullary endosomes are differentially sensitive to Sch-28080 and omeprazole. Am J Physiol 1994 266 : F868 77.